A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Ortho Tricyclen Side Effects, and Drug Interactions - Norgestimate and Ethinyl Estradiol
Ortho Tricyclen Side Effects, and Drug Interactions - Norgestimate and Ethinyl Estradiol
SIDE EFFECTS
An increased risk of the
following serious adverse reactions has been associated with the
use of oral contraceptives
(See WARNINGS Section).
Thrombophlebitis and venous
thrombosis with or
without embolism
Arterial thromboembolism
Pulmonary embolism
Myocardial infarction
Cerebral hemorrhage
Cerebral thrombosis
Hypertension
Gallbladder disease
Hepatic adenomas or benign
liver tumors
The following adverse reactions have been reported in patients
receiving oral contraceptives and are believed to be drug-related:
Nausea
Vomiting
Gastrointestinal symptoms (such as abdominal
cramps and bloating)
Breakthrough bleeding
Spotting
Change in menstrual flow
Amenorrhea
Temporary infertility
after discontinuation of treatment
Edema
Melasma which may persist
Breast changes: tenderness, enlargement, secretion
Change in weight
(increase or decrease)
Change in cervical
erosion and secretion
Diminution in lactation
when given immediately postpartum
Cholestatic jaundice
Migraine
Rash (allergic)
Mental depression
Reduced tolerance
to carbohydrates
Vaginal candidiasis
Change in corneal curvature
(steepening)
Intolerance to contact
lenses
The following adverse reactions have been reported in users of
oral contraceptives and the association
has been neither confirmed nor refuted:
Pre-menstrual syndrome
Cataracts
Changes in appetite
Cystitis-like syndrome
Headache
Nervousness
Dizziness
Hirsutism
Loss of scalp hair
Erythema multiforme
Erythema nodosum
Hemorrhagic eruption
Vaginitis
Porphyria
Impaired renal function
Hemolytic uremic
syndrome
Acne
Changes in libido
Colitis
Budd-Chiari Syndrome
DRUG INTERACTIONS
Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been
associated with concomitant use of rifampin. A similar association, though less marked, has been suggested
with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly
with ampicillin and tetracyclines 72. A possible interaction has been suggested with hormonal contraceptives
and the herbal supplement St. John’s Wort based on some reports of oral contraceptive users experiencing
breakthrough bleeding shortly after starting St. John’s Wort. Pregnancies have been reported by users of
combined hormonal contraceptives who also used some form of St. John’s Wort. Healthcare prescribers are
advised to consult the package inserts of medication administered concomitantly with oral contraceptives.
See also PRECAUTIONS,
WARNINGS sections
top
